Achison Inc.
ACHN
Other OTC0.79
USD
-0.22
- -
CIK
0001672571
ISIN
US00449Q1013
CUSIP
00449Q101
Return %
Stock
S&P500
1Y
285.95
26.84
3Y
55.14
77.03
5Y
55.14
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Barry Wan
- Sector
- Communication Services
- Industry
- Advertising Agencies
- Address
- 135-22 Northern Boulevard Flushing NY United States of America 11354
- IPO Date
- Oct 19, 2021
- CIK
- 0001672571
- Similar Companies
- Business
- Achison Inc. (NYSE: ACHN) operates as a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies targeting serious diseases, particularly in oncology and rare genetic disorders; its core pipeline includes targeted small molecule inhibitors such as oral drugs for hedgehog pathway inhibition and immuno-oncology agents; the company also provides contract research services and licensing agreements for proprietary compounds. Founded in 1994 and headquartered in Canton, Massachusetts, Achison serves pharmaceutical partners, healthcare providers, and patients primarily in North America and Europe, with expanding operations into Asia-Pacific markets through clinical trial collaborations. In late 2024, Achison announced a strategic merger with a leading immuno-oncology firm, enhancing its pipeline with two Phase III candidates; earlier in 2025, the company completed a $250 million funding round led by venture capital investors to support commercial launches; additionally, it rebranded select subsidiaries under a unified precision medicine division following regulatory approvals for its flagship hedgehog inhibitor in multiple indications.